Although patients have benefited from the expansion of options, questions have arisen about how to select optimal treatment, such as whether to recommend lymph node dissection or immunotherapy compared with targeted therapy.
Median overall survival (OS) was 7.4 months longer among patients with platinum-sensitive, relapsed ovarian cancer who were given chemotherapy with cediranib followed by maintenance therapy with cediranib in the ICON6 trial.
Not only did lymphadenectomy yield no improvement in overall survival, but patients who underwent the procedure faced greater morbidity in terms of serious postoperative complications and greater early mortality following surgery.
Abemaciclib combined with the estrogen inhibitor fulvestrant may significantly reduce the risk of disease progression and increase the objective response rate in women with metastatic breast cancer, according to the results of the MONARCH 2 study.
Two studies presented during the 2017 ASCO Annual Meeting provided additional evidence of the efficacy and safety of the CDK4/6 inhibitor ribociclib plus letrozole as a first-line treatment for ER-positive/HER2-negative advanced breast cancer.